Copyright
©The Author(s) 2016.
World J Gastroenterol. Aug 28, 2016; 22(32): 7252-7263
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7252
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7252
Ref. | Group | Patient number | Therapy for HCC | Male/Female | Age (yr) | Child-Pugh A/B/C | Maximum tumor size (mm) | Study design |
Togo et al[41] | BCAA | 21 | Surgery | 17/4 | 66.5 ± 4.5 | 15/7/0 | ND | RCT |
2005 | control | 22 | 17/5 | 64.3 ± 9.1 | 17/5/0 | ND | ||
Ichikawa et al[42] | BCAA | 26 | Surgery | 18/8 | 64.7 ± 9.8 | 21/5/0 | ND | RCT |
2012 | control | 30 | 20/10 | 64.5 ± 11.4 | 25/5/0 | ND | ||
Nishikawa et al[43] | BCAA | 115 | RFA | 64/51 | 69.3 ± 9.4 | 83/30/2 | 19.5 ± 6.0 | cohort |
2013 | control | 141 | 85/58 | 70.9 ± 7.8 | 88/52/1 | 19.6 ± 6.6 | ||
Yoshiji et al[44] | BCAA | 51 | RFA | 32/19 | 63.6 ± 15.3 | 41/10/0 | ND | RCT |
2013 | control | 42 | 25/17 | 62.2 ± 14.8 | 33/9/0 | ND | ||
Saito et al[45] | BCAA | 13 | RFA | 8/5 | 73.4 ± 2.2 | 83/30/2 | ND | cohort |
2014 | control | 27 | 16/11 | 70.0 ± 1.9 | 88/52/1 | ND | ||
Nishikawa et al[46] | BCAA | 40 | TACE | 27/13 | 69.9 ± 8.8 | 6.4 ± 0.4 | 33.4 ± 16.7 | cohort |
2012 | control | 59 | 32/27 | 73.2 ± 10.1 | 5.4 ± 0.1 | 35.9 ± 14.7 | ||
(score) | ||||||||
Takeda et al[47] | BCAA | 34 | Sorafenib | 27/7 | 72 (55-88) | 16/18/0 | ND | cohort |
2014 | control | 44 | 37/7 | 68 (46-89) | 30/14/0 | ND | ||
Imanaka et al[48] | BCAA | 55 | Sorafenib | 45/10 | 72.2 ± 7.8/73.1 ± 6.4 | 37/18/0 | ND | cohort |
2015 | control | 201 | 167/34 | 72.4 ± 8.8/67.2 ± 13.0 | 179/22/0 | ND | ||
(Child-Pugh A/B) |
Ref. | Group | Patient number | Therapy for HCC | Male/Female | Age (yr) | Child-Pugh A/B/C | Maximum tumor size (mm) | Study design |
Okabayashi et al[56] | LES-BCAA | 40 | surgery | 29/11 | 65.7 ± 8.6 | 33/7/0 | ND | cohort |
2008 | control | 72 | 55/17 | 68.3 ± 8.1 | 62/10/0 | ND | ||
Kuroda et al[57] | LES-BCAA | 20 | RFA | 13/7 | 65.6 ± 7.0 | 8/11/1 | 20.2 (median) | cohort |
2010 | control | 15 | 9/6 | 66.0 ± 8.1 | 6/8/1 | 19.8 (median) | ||
Morihara et al[58] | LES-BCAA | 10 | RFA | 8/2 | 73.5 ± 8.5 | 9/1/0 | 20.0 ± 10.7 | RCT |
2012 | Morning-BCAA | 10 | 8/2 | 66.9 ± 9.7 | 7/3/0 | 24.3 ± 7.7 | ||
control | 10 | 7/3 | 69.3 ± 8.0 | 7/3/0 | 24.4 ± 7.7 | |||
Takeshita et al[59] | LES-BCAA | 28 | TACE | 19/9 | 69.1 ± 8.231 | 6.107 ± 1.315 (score) | ND | RCT |
2009 | control | 28 | 21/7 | 70.6 ± 9.745 | 5.53 ± 0.516 (score) | ND | ||
Harima et al[60] | LES-BCAA | 13 | HAIC | 11/2 | 64.5 ± 9.5 | 6/7/0 | 77.7 ± 50.5 | RCT |
2010 | control | 10 | 8/2 | 66.4 ± 12.8 | 6/4/0 | 88.0 ± 39.7 |
- Citation: Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263
- URL: https://www.wjgnet.com/1007-9327/full/v22/i32/7252.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i32.7252